Cellular senescence: from mechanisms to current biomarkers and senotherapies
V Lucas, C Cavadas, CA Aveleira, V Hook - Pharmacological Reviews, 2023 - Elsevier
An increase in life expectancy in developed countries has led to a surge of chronic aging-
related diseases. In the last few decades, several studies have provided evidence of the …
related diseases. In the last few decades, several studies have provided evidence of the …
[HTML][HTML] Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: pathogenic mechanisms and therapeutic potential
Abstract Alzheimer's disease (AD), the most common neurodegenerative disorder, is
characterized by memory loss and cognitive dysfunction. The accumulation of misfolded …
characterized by memory loss and cognitive dysfunction. The accumulation of misfolded …
Protein adsorption is required for stealth effect of poly (ethylene glycol)-and poly (phosphoester)-coated nanocarriers
S Schöttler, G Becker, S Winzen, T Steinbach… - Nature …, 2016 - nature.com
The current gold standard to reduce non-specific cellular uptake of drug delivery vehicles is
by covalent attachment of poly (ethylene glycol)(PEG). It is thought that PEG can reduce …
by covalent attachment of poly (ethylene glycol)(PEG). It is thought that PEG can reduce …
The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells
K Taketo, M Konno, A Asai… - International …, 2017 - spandidos-publications.com
N 6-methyladenosine (m6A) is the most abundant epitranscriptome modification in
mammalian mRNA. Recent years have seen substantial progress in m6A epitranscriptomics …
mammalian mRNA. Recent years have seen substantial progress in m6A epitranscriptomics …
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
L Shaashua, A Ben-Shmuel, M Pevsner-Fischer… - Nature …, 2022 - nature.com
Tumors initiate by mutations in cancer cells, and progress through interactions of the cancer
cells with non-malignant cells of the tumor microenvironment. Major players in the tumor …
cells with non-malignant cells of the tumor microenvironment. Major players in the tumor …
Bone marrow–derived fibroblasts are a functionally distinct stromal cell population in breast cancer
Cancer-associated fibroblasts (CAFs) are highly prominent in breast tumors, but their
functional heterogeneity and origin are still largely unresolved. We report that bone marrow …
functional heterogeneity and origin are still largely unresolved. We report that bone marrow …
Protection of host cells by complement regulators
CQ Schmidt, JD Lambris, D Ricklin - Immunological reviews, 2016 - Wiley Online Library
The complement cascade is an ancient immune‐surveillance system that not only provides
protection from pathogen invasion but has also evolved to participate in physiological …
protection from pathogen invasion but has also evolved to participate in physiological …
Multi-omics analysis reveals the chemoresistance mechanism of proliferating tissue-resident macrophages in PDAC via metabolic adaptation
J Zhang, J Song, S Tang, Y Zhao, L Wang, Y Luo… - Cell Reports, 2023 - cell.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer that typically
demonstrates resistance to chemotherapy. Tumor-associated macrophages (TAMs) are …
demonstrates resistance to chemotherapy. Tumor-associated macrophages (TAMs) are …
Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and is largely refractory to
available treatments. Identifying key pathways associated with disease aggressiveness and …
available treatments. Identifying key pathways associated with disease aggressiveness and …
[HTML][HTML] The evolution of chemotherapy for the treatment of prostate cancer
DI Quinn, HM Sandler, LG Horvath, A Goldkorn… - Annals of …, 2017 - Elsevier
Chemotherapy has been explored as a treatment option for metastatic prostate cancer since
the early 1980s. Docetaxel, a taxane chemotherapeutic, was approved for the treatment of …
the early 1980s. Docetaxel, a taxane chemotherapeutic, was approved for the treatment of …